prikaz prve stranice dokumenta Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
  Preuzmi
PDF 718.46 KB
Znanstveni rad - Izvorni znanstveni rad
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
Clinical Research in Cardiology, 111 (2022), 5; 560-573. https://doi.org/10.1007/s00392-022-01996-2
(GLORIA-AF) Lip, Gregory Y. H.; ...; Kes, Vanja Basic; Kalan, Marica Bracic; Brkljacic, Diana Delic; Knezevic, Aleksandar; Kovacic, Dragan; Nazlić, Jurica; Persic, Viktor; Pivac, Nediljko; Poljakovic, Zdravka

Citiranost:
,
Citirajte ovaj rad

Lip, G. Y. H., Kes, V. B., Kalan, M. B., Brkljacic, D. D., Knezevic, A., Kovacic, D. ... Poljakovic, Z. (2022). Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clinical Research in Cardiology, 111. (5), 560-573. doi: 10.1007/s00392-022-01996-2

Lip, Gregory Y. H., et al. "Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry." Clinical Research in Cardiology, vol. 111, br. 5, 2022, str. 560-573. https://doi.org/10.1007/s00392-022-01996-2

Lip, Gregory Y. H., Vanja Basic Kes, Marica Bracic Kalan, Diana Delic Brkljacic, Aleksandar Knezevic, Dragan Kovacic, Jurica Nazlić, Viktor Persic, Nediljko Pivac i Zdravka Poljakovic. "Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry." Clinical Research in Cardiology 111, br. 5 (2022): 560-573. https://doi.org/10.1007/s00392-022-01996-2

Lip, G. Y. H., et al. (2022) 'Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry', Clinical Research in Cardiology, 111(5), str. 560-573. doi: 10.1007/s00392-022-01996-2

Lip GYH, Kes VB, Kalan MB, Brkljacic DD, Knezevic A, Kovacic D, i sur.. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clinical Research in Cardiology [Internet]. 16.03.2022. [pristupljeno 24.03.2025.];111(5):560-573. doi: 10.1007/s00392-022-01996-2

G. Y. H. Lip, et al., "Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry", Clinical Research in Cardiology, vol. 111, br. 5, str. 560-573, Ožujak 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:815775. [Citirano: 24.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:815775
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
AutorGregory Y. H. Lip
Autor
...
AutorVanja Basic Kes
AutorMarica Bracic Kalan
AutorDiana Delic Brkljacic
AutorAleksandar Knezevic
AutorDragan Kovacic
AutorJurica Nazlić
AutorViktor Persic
AutorNediljko Pivac
AutorZdravka Poljakovic
KolaboracijaGLORIA-AF
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or... Više apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaClinical Research in Cardiology
Brojčani podacivol. 111, br. 5, str. 560-573
p-ISSN1861-0684
e-ISSN1861-0692
DOIhttps://doi.org/10.1007/s00392-022-01996-2
URN:NBNurn:nbn:hr:220:815775
Datum objave publikacije2022-03-16
URL dokumentahttps://link.springer.com/10.1007/s00392-022-01996-2
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-06-25 11:20:27
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.